TY - JOUR
T1 - Trends in the risk of cardiovascular disease in women with breast cancer in a Dutch nationwide cohort study
AU - Buddeke, Josefien
AU - Gernaat, Sofie A. M.
AU - Bots, Michiel L.
AU - van den Bongard, Desiree H. J. G.
AU - Grobbee, Diederick E.
AU - Vaartjes, Ilonca
AU - Verkooijen, Helena M.
N1 - Funding Information:
Acknowledgements JB and IV were supported by an unrestricted grant ‘Facts and Figures’ from the Netherlands Heart Foundation.
Publisher Copyright:
© 2019 Author(s).
PY - 2019/5
Y1 - 2019/5
N2 - Objectives: To investigate trends in cardiovascular disease (CVD) risk following breast cancer using national registry data. Methods: A nationwide cohort study was conducted, comprising 163 881 women with in situ (7.6%) or invasive (92.4%) breast cancer and women of the general population, ranging from 3 661 141 in 1996 to 4 566 573 in 2010. CVD mortality rate in women with and without breast cancer and hospitalisation rate after breast cancer were calculated for the years 1996-2010. Age-adjusted CVD and breast cancer mortality within 5 years after breast cancer admission (1997-2010) were compared with 1996 calculated with a Cox proportional hazard analysis. Results: The absolute 10-year CVD mortality risk following breast cancer decreased from 56 per 1000 women in 1996 to 41 in 2005 (relative reduction=27.8%). In the general population, this decreased from 73 per 1000 women in 1996 to 55 in 2005 (-23.9%). The absolute risk of CVD hospitalisation within 1 year following breast cancer increased from 54 per 1000 women in 1996 to 67 in 2009 (+23.6%), which was largely explained by an increase in hospitalisation for hypertension, pulmonary embolism, rheumatoid heart/valve disease and heart failure. The 5-year CVD mortality risk was 42% lower (HR 0.58, 95% CI=0.48 to 0.70) for women admitted for breast cancer in 2010 compared with 1996. Conclusions: CVD mortality risk decreased in women with breast cancer and in women of the general population, with women with breast cancer having a lower risk of CVD mortality. By contrast, there was an increase in hospitalisation for CVD in women with breast cancer.
AB - Objectives: To investigate trends in cardiovascular disease (CVD) risk following breast cancer using national registry data. Methods: A nationwide cohort study was conducted, comprising 163 881 women with in situ (7.6%) or invasive (92.4%) breast cancer and women of the general population, ranging from 3 661 141 in 1996 to 4 566 573 in 2010. CVD mortality rate in women with and without breast cancer and hospitalisation rate after breast cancer were calculated for the years 1996-2010. Age-adjusted CVD and breast cancer mortality within 5 years after breast cancer admission (1997-2010) were compared with 1996 calculated with a Cox proportional hazard analysis. Results: The absolute 10-year CVD mortality risk following breast cancer decreased from 56 per 1000 women in 1996 to 41 in 2005 (relative reduction=27.8%). In the general population, this decreased from 73 per 1000 women in 1996 to 55 in 2005 (-23.9%). The absolute risk of CVD hospitalisation within 1 year following breast cancer increased from 54 per 1000 women in 1996 to 67 in 2009 (+23.6%), which was largely explained by an increase in hospitalisation for hypertension, pulmonary embolism, rheumatoid heart/valve disease and heart failure. The 5-year CVD mortality risk was 42% lower (HR 0.58, 95% CI=0.48 to 0.70) for women admitted for breast cancer in 2010 compared with 1996. Conclusions: CVD mortality risk decreased in women with breast cancer and in women of the general population, with women with breast cancer having a lower risk of CVD mortality. By contrast, there was an increase in hospitalisation for CVD in women with breast cancer.
KW - breast cancer
KW - cardiotoxicity
KW - cardiovascular disease
KW - morbidity
KW - mortality
KW - trends
UR - http://www.scopus.com/inward/record.url?scp=85066621618&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2018-022664
DO - 10.1136/bmjopen-2018-022664
M3 - Article
C2 - 31152022
SN - 2044-6055
VL - 9
SP - e022664
JO - BMJ Open
JF - BMJ Open
IS - 5
M1 - e022664
ER -